aspecte clinico-diagnostice - Ion Mereuta

Ion Mereuţă, Iraida Iacovlev, Oxana Pihut
44. Even-Sapir E., U. Metser, E. Mishani .The detection of bone metastasis in
patients with high – risk prostate cancer: 99m Tc – MDP Planar bone scintigraphy,
single – and multi- field - of – view SPECT, 18F – fluoride PET, and 18F – fluoride
PET/CT. In: Journal of Nuclear Medicine. 2006, vol. 47, nr 2, p. 287-297.
45. Falavigna A., Righesso Neto O., Loppi A.E. Metastatic tumor of thoracic
and lumbar spine: prospective study comparing the surgery and radiotherapy vs
external immobilization with radiotherapy. In: Arq Neuropsiquiatr. 2007, vol. 65, nr
3B, p. 889-895.
46. Farag S.S. et al. Delay by internists in obtaining diagnostic biopsies in
patients with suspected cancer. In: Ann. Intern. Med. 1992, vol. 116, p. 473.
47. Feienmesser R., Feienmesser M. et al. Detection of occult nasopharyngeal
primary tumors by means of in situ hybridization. In: J. Laryngol/Otol. 1992, vol.
106, nr 4, p.345-348.
48. Feun L.G, Savarag N. Detection of occult bone metastasis by MRI scan. In:
J.Fl.Med.Assoc. 1990, vol. 77, nr 10, p.881-883.
49. Font W.F., Cordies J.N., Diaz S.C., Solano L.P. Sistematica diagnostica
frente a una metastasis sin tumor primario conocido. In: Rev.cub.oncol. 1989, vol.
5, nr 1-2, p.9-15.
50. Frost P., Raber M., Ambbrtzzese J.L. Unknown primary tumors as a unique
clinical and biologic entity a hypothesis. In: Cancer Bull. 1989, vol. 41, nr 3,
p.139-141.
51. Fujimoto R., Higashi T., NakamotoY. Diagnostic accuracy of bone
metastasis detection in cancer patients: comparison between bone scintigraphy
and whole – body FDG – PET. In: Annals of Nuclear Medicine. 2006, vol. 26, nr 6,
p.399-408.
52. Gambardella G., Santamaria L.B et al. Brain metastases: surgical versus
conservative treatment. In: J. Neurosurg. 1990, vol. 34, nr 3-4, p. 309-314.
53. Gamble A.R, Bell J. A. et al. Use of tumour marker immunoreactivity to
identify primary site of metastatic cancer. In: Brith.Med. J. 1993, vol. 306, nr 1,
p.295-298.
54. Gatter K.C., Alcock C., Heryet A., Mason D.Y. Clinical importance of
analysing malignant tumors of uncertain origin with immunogistological
techniques. In: The Lancet. 1985, nr 6, p.1302-1305.
55. Ghanem N., Kelly T., Altehoefer C. Whole-body MRI in comparison to
skeletal scintigraphy for detection of skeletal metastases in patients with solid
tumors. In: Radiologe. 2004, vol. 44, nr 9, p. 864-873.
56. Ghidirim N., Mustea A., Popescu C. Tumorile urogenitale. In: Ghid clinic de
oncologie. Chişinău. 2003, p.
57. Gil G.M., Vadell N.C., Farbegat M.X. et al. Yield of diagnostic tests in
neoplasms of unknown origin. A retrospective study. In: Rev. Clin. Esp. 1990, vol.
186 (6), nr 4, p.252-258.
88
Aspecte clinico-diagnostice ale tumorilor maligne secundare cu focare primare necunoscute
58. Giuffri G., Muscarella A. Malignant hypomelanotic melanoma of mules. A
histologic, immunohistochemical and ultrastructural study of a case with unknown
primary site and widespread metastases. In: Pathologica. 1995 Feb., vol. 87, nr 1,
p.100-104.
59. Gluckman J.L., Robbins K.T., Fried M.P. Cervical metastatic squamous
carcinoma of unknown or occult primary source. In: Head-Neck. 1990, vol. 12, nr
5, p. 440-443.
60. Greco F. A., Hainsworth J.D. Tumors of unknown origin. In: CA. Cancer J.
Clin. 1992, vol. 42, nr 2, p.96-115.
61. Guarishi A., Keane T.J., Elhacim T. Metastatic inguinal nodes from an
unknown primary neoplasm: a review of 56 cases. In: Cancer. 1987, vol. 59, nr 3, p.
572-577.
62. Guthrie T.H. Treatable carcinoma of unknown origin. In: Amer.J.Med.Sci.
1989, vol. 298, nr 2, p.74-78.
63. Hackländer T., Scharwächter C., Golz R. Value of diffusion-weighted
imaging for diagnosing vertebral metastases due to prostate cancer in comparison
to other primary tumors. In: Rofo. 2006, vol. 178, nr 4, p. 416-424.
64. Hainsworth J.D., Greco F. A. Poorly differentiated carcinoma and poorly
differentiated adenocarcinoma of unknown primary site. In: Sem.Oncol. 1993, vol.
20, nr 6, p. 279-286.
65. Hainsworth J.D., Greco F. A. Treatment of patients with cancer of unknown
primary site. In: Imp. Adv.Oncol. 1991, nr 7, p.173-190.
66. Hamann G., Meier T., Schimrigk K. Brain metastases as an initial
manifestation of tumor disease. In: Nerv. 1993, vol. 64, nr 2, p. 54-57.
67. Hanna W.M., Kahn H.J. The ultrastructure of metastatic adenocarcinoma
in serous fluids: an aid in identification of primary site of the neoplasm. In: Acta
Cytol. 1985, vol. 29, nr 3, p. 206-210.
68. Harada M., Iida M., Yamaguchi M. Analysis of bone metastasis of prostati
adenocarcinoma in 137 autopsy cases. In: Adv. Exp. Med. Biol. 1992, vol. 324,
p. 173-182.
69. Harper C.L., Lofts F.J., Otter M. et al. Prostate- specific antigen (PSA)
immunohistochemistry in the presence of a normal serum PSA as an aid to
diagnosis of adenocarcinoma of unknown primary site. In: Br.J.Hosp.Med. 1996
Mar.20-Apr.2, vol. 55, nr 6, p. 367-368.
70. Hartwig E., Kinzl L., Schultheiss M. Complications of malignant tumors –
pathological fractures. In: MMW Fortschr. Med. 2004, vol. 146, nr 21, p. 31-32.
71. Haseman M.K., Brown D.W. et al. Radioimmunodetection of occult
carcinoembryonic antigen- produting cancer. In: L.Nucl.Med. 1992, vol. 33, nr 10,
p. 1750-1756.
72. Haskell C.M., Cochran A.J., Barsky S.H. et al. Metastasis of unknown
origin. In: Current Problems in Cancer. 1988, vol.12, nr 1, p.1-58.
89